1. Introduction {#sec1}
===============

Alzheimer's disease (AD), the most common and severe form of dementia, has remained elusive and needs further understanding at the molecular level. The most common symptoms of this disease are cognitive loss, dementia, behavioral discrepancy, etc.^[@ref1]^ The multidirectional nature of AD makes it extremely challenging to achieve effective therapy for this devastating disease.^[@ref2]^ Major advancements in disease progression through molecular-level understanding in the last decade have established several hypotheses related to AD such as (i) the cholinergic hypothesis,^[@ref3]−[@ref5]^ (ii) amyloid hypothesis,^[@ref6]^ (iii) metal ion hypothesis,^[@ref7]^ (iv) Tau hypothesis,^[@ref8]^ (v) oxidative stress,^[@ref9]^ etc. Among these, generation of senile plaques from deposits of amyloid-β (Aβ) has always been suspected of playing a significant role in disease progression. Moreover, it is also suspected of having a mutual relationship with all other pathological hypotheses.^[@ref4]^

The Aβ peptide (40--42 amino acid-long amphiphilic peptide) undergoes a self-assembling process and forms oligomeric aggregates followed by fibrillar aggregates.^[@ref10]^ These aggregates are mainly considered to be the cause of Aβ-mediated toxicity.^[@ref11]^ Therefore, the development of a chemical modulator that can prevent the aggregation of the Aβ peptide had been a significant focus for AD treatment.^[@ref12]^ Recent literature reports reveal many peptide-based molecules that have been designed and explored based on their inhibitory role in Aβ aggregation. Tjernberg et al. demonstrated that the KLVFF short peptide, the 16--20 residues of the Aβ hydrophobic core, inhibits the aggregation of Aβ.^[@ref13]^ Rajasekhar et al. showed that peptide residues KLVFF from the Aβ hydrophobic core can act as a recognition moiety and can be modified to develop multifunctional therapeutics against AD.^[@ref14]^ Lowe et al. showcased that attaching a lysine hexamer to the recognition moiety as a disrupting element decreases Aβ-mediated toxicity.^[@ref15]^ Soto et al. modified the recognition moiety KLVFFA and constituted a pentapeptide (LPFFD) that has antifibrillary activity.^[@ref16]^

The brain strictly scrutinizes the transport of biometals (such as Cu^2+^, Zn^2+^, Fe^2+^, Ca^2+^) required for its normal functioning.^[@ref17]^ It has been documented before that disbalance in neuronal homeostasis of these metal ions may play a crucial role in AD pathogenesis.^[@ref18]^ Moreover, the metal ion hypothesis has always linked the presence of redox-active bio-metals to the generation of reactive oxygen species (ROS) that induce Aβ toxicity.^[@ref19]^ Although initially Aβ was believed to produce ROS voluntarily,^[@ref20]^ later on, it was reported that the presence of metals is necessary for the production of ROS in the AD brain.^[@ref21]^ Among all the metals, copper has always been found in amyloid plaques at high concentrations (∼0.4 mM), which accelerates amyloid aggregation.^[@ref22]^ At the oxidized state, Cu^2+^ binds to Aβ, receives an electron from methionine (Met-35), and gets reduced to the Aβ--Cu^+^ state, which is catalyzed by biological reductants like ascorbate.^[@ref23]^ Due to its excessive metabolic needs, the brain consumes 20% of the total oxygen of the body. Therefore, the brain is considered to be the most oxygen abundant organ compared to any other organs in the body.^[@ref24]^ Aβ--Cu^+^ takes part in an uncontrolled redox reaction and reduces these abundant molecular oxygens, eventuating H~2~O~2~.^[@ref25]^ This H~2~O~2~, later on, participates in a Fenton-type reaction with Aβ--Cu^+^ and generates hydroxyl radicals (^·^OH), in turn causing oxidative stress and finally neuronal death in the AD brain.^[@ref26]^ Many metal ion chelators have been developed and also been reported to reduce Aβ--Cu^2+^-mediated ROS production and its toxicity. Clioquinol (CQ) and 8-hydroxyquinoline (PBT2) have been shown to chelate copper and to cause improvement against ROS-mediated toxicity.^[@ref27]^ Qu et al. adopted the same fashion and cast CQ on nanoparticles, which showed a successful reduction of ROS-mediated toxicity in the AD brain.^[@ref28]^ Although ROS-mediated toxicity was reduced through chelating copper, extracellularly assembled Aβ peptides aggregate to form toxic oligomers and finally developed into fibrils.

As a whole, multifactorial toxicity induced by Aβ with or without the involvement of metals leads to neuronal damage and disease advancement. Although different approaches have been used against the Aβ-mediated toxicity (either a β-sheet breaker or metal chelator), all these approaches alone have failed to work satisfactorily in AD treatment. Therefore, developing a multifunctional chemical component that can inhibit Aβ aggregation along with its ROS-mediated toxicity through metal sequestration from the Aβ--Cu^2+^ complex would be a highly favorable approach. In this context, various bifunctional peptide molecules have been designed and investigated according to their ability to disaggregate Aβ and their ability to interfere with metal-mediated ROS generation. Faller et al. discovered Aβ 12--20 and 13--20 residues to have an inhibitory aggregation effect along with a metal chelating ability.^[@ref29]^ Yuan et al. followed a similar way and formulated bifunctional peptide GGHRYYAAFFARR (GR), where the sequence GGH is used for metal chelation and the rest of the sequence was used to create an inhibitory aggregation effect.^[@ref30]^ Recently, Rajasekhar et al. interestingly modified the recognition moiety KLVFF using sarcosine and attached a natural copper-chelating sequence GHK to form SrVSrFSrGHK (P6), which showed both aggregation-inhibiting and metal-chelating properties.^[@ref31]^ The human body contains several naturally occurring metal chelating peptide motifs known as the amino terminal Cu^2+^- and Ni^2+^-binding motif (ATCUN).^[@ref32]^ Biologically available proteins or peptides containing these motifs have specific selectivity and high affinity toward the metal ions. Only a small number of studies have shown whether these motifs can be utilized as peptide metal chelators. In this context, Asp-Ala-His-Lys (DAHK), a natural tetrapeptide ATCUN derived from human serum albumin (HSA), can be modified to constitute a multidirectional inhibitor for Aβ toxicity. A chemically synthesized DAHK motif of HSA binds to Cu^2+^ predominantly in a 1:1 stoichiometry with binding affinity of *K*~a~ ∼ 10^14^ for Cu^2+^, which is much higher than of A β's Cu^2+^ binding affinity of *K*~a~ ∼ 10^9^.^[@ref33]^ Upon chelating to DAHK, Cu^2+^ gets bound into a square planar geometry. This type of structure hinders the reduction of Cu^2+^ to Cu^+^ as Cu^+^ prefers a tetrahedral geometry. The inhibition of this reduction, in turn, terminates the whole redox cycle.^[@ref34]−[@ref36]^ Although it is the most abundant protein in blood serum (concentration of -640 μM), HSA is present in a relatively smaller amount (3 M) in cerebrospinal fluid (CSF).^[@ref37]^ This can be correlated with increased ROS-mediated toxicity in the AD brain as the smaller abundance of HSA in CSF limits the presence of DAHK in the brain. To counter this, chemically synthesized DAHK containing a peptide-mimicking inhibitor of multifaceted Aβ toxicity has been conceptualized in this article. Moreover, to justify its relevance, it has been reported that synthesized DAHK alone can reduce copper-mediated ROS induction and neuronal toxicity.^[@ref32]^

In this study, DAHK has been thoughtfully coupled with the Aβ42 recognition moiety, LPFFD, which on its own has an Aβ aggregation inhibitory effect. As a whole, this newly synthesized molecule is expected to show multidirectional activity through Aβ aggregation inhibition and reduction of ROS-generated toxicity through copper chelation. Besides, due to its much higher binding affinity, it is also expected to chelate out copper from the Aβ--Cu^2+^ complex. Despite being designed to be a potent inhibitor of Aβ aggregation and ROS generation, this molecule is not equipped to overcome the concern regarding the peptide's instability in biological conditions. The peptide's susceptibility to serum proteases has been a major obstacle in its use as a synthesized therapeutic component.^[@ref38]^ In recent studies, several strategies such as N-substitution, cyclization, incorporation of sarcosine, turn mimetics, and glycoconjugation have shown to increase the peptide's stability in biological conditions.^[@ref39]^ Among these, glycoconjugation has shown an additional propensity to increase the Aβ disaggregation by peptide molecules.^[@ref40]^ Sinopoli et al. showed in their work that attaching a monosaccharide trehalose molecule to recognition moiety LPFFD not only enhanced its serum stability but also showed an increased disaggregation of Aβ aggregates.^[@ref41]^ It has also been speculated that just covalently attaching a monosaccharide unit to a short-sequence peptide can introduce steric hindrance and thus help the peptide participate in disaggregation.^[@ref42]^ On this basis, the designed nonapeptide sequence (LPFFDDAHK) is modified by conjugating a glucose molecule through thio-coupling, thus constructing the glycopeptide, Glupep. The glycocomponent upon getting coupled to a peptide is anticipated to enhance the peptide's stability against serum proteases and also augments its aggregation disruption ability. Different techniques such as the thioflavin-T (ThT) assay and dot blot analysis were carried out to determine the Aβ aggregation inhibitory ability of Glupep ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}). The metal sequestration ability of Glupep (from the Aβ--Cu^2+^ inclusion complex) was evaluated in vitro using the tyrosine quenching assay. Later on, several in vitro studies have been performed to investigate the antioxidant property of Glupep. To examine the stability and bioavailability of the Glupep conjugate, a serum stability assay was performed. The therapeutic possibility of Glupep was then validated in vitro in PC12-derived neurons. Overall, the studies reveal that structurally tuned, multifunctional Glupep effectively altered vital aspects of toxicity caused by Aβ in AD.

2. Results and Discussion {#sec2}
=========================

2.1. Design Strategy {#sec2.1}
--------------------

As discussed earlier, here, we have adopted a bioinspired strategy to design Glupep from human serum albumin (HSA). Its copper-chelating motif (DAHK) has been coupled with a β*-*sheet breaker peptide (LPFFD), to stop the generation of reactive oxygen species (ROS),^[@ref43]^ and a glucose moiety has been coupled with the N-terminal of the nonapeptide to enhance its serum stability, bioavailability, and membrane permeability ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref44]^ This glycopeptide (Glupep) is expected to inhibit the redox cycle by extracting Cu^2+^ from the Aβ42--Cu^2+^complex and impede Cu^2+^-dependent and Cu^2+^-independent aggregation of Aβ42.

![Schematic representation of the design concept of glycopeptide "Glupep".](ao0c01028_0001){#fig1}

2.2. ThT Assay to Explore the Inhibitory Effect on Aβ42 Fibrillation {#sec2.2}
--------------------------------------------------------------------

Aβ42 fibrils play a crucial role in disease progression in the AD brain. Therefore, inhibiting the formation of these aggregates is regarded as one of the most crucial strategies for designing effective therapeutics for AD. The thioflavin-T (ThT) assay was performed to understand the effect of Glupep on Aβ fibrillation. ThT (λ~ex~ = 445 nm, λ~em~ = 485 nm), a benzothiazole-based fluorescent dye, shows minimum fluorescence in the presence of Aβ42 monomers, but an increment in fluorescence occurs when it interacts with mature Aβ aggregates.^[@ref45]^ Therefore, the change in fluorescence intensity of ThT can be considered as a marker for Aβ fibrillation alteration. For this study, Aβ42 (10 μM) was incubated alone (control) and co-incubated separately in the presence of different concentrations of Glupep (2.5--20 μM) at 37 °C with constant agitation for 48 h. Then, the fluorescence intensity of the ThT was measured at 485 nm to estimate the effect of increasing concentration on fibrillation. From the ThT fluorescence intensity, it is prominent that with an increment in the concentration, inhibition of fibrillation also improved ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). Thus, this implies Glupep to have a dose-dependent inhibitory effect on Aβ42 fibrillation. Further, Glupep (10 μM), LPFFD (10 μM), DAHK (10 μM), and glucose (10 μM) were co-incubated with a fixed concentration of Aβ42 (10 μM) to estimate the effect of increasing concentration on fibrillation. From the results ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C), it is prominent that glucose and DAHK have the least significant effect on Aβ42 fibrillation. LPFFD (positive control) showed a 32% decrease of fluorescence intensity, indicating an effective inhibition. Surprisingly, Glupep showed a 63% reduction in the ThT fluorescence intensity, reflecting the significant inhibitory effect on Aβ42 fibrillation, which is 30% greater inhibition than that of the positive control with an increment in the concentration, and inhibition of fibrillation also improved.

![(A) Inhibition of amyloid fibrillation detected through the ThT assay in the presence of Glupep in different concentrations. (B) Assessment of inhibition of amyloid fibrillation using the dot blot assay. (C) Bar diagram of the ThT assay to detect the inhibition of components (Glucose, LPFFD, and DAHK). (D) ThT assay of amyloid oligomer inhibition in the presence of Glupep in different increasing concentrations. (E) Dot blot assay to detect inhibition of amyloid oligomerization in increasing Glupep concentrations. (F) Histogram of the ThT assay with various components (glucose, LPFFD, and DAHK) for amyloid oligomer inhibition. Error bar corresponds to the standard deviation of the value (\**p* ≤ 0.05) of the normalized fluorescence intensity (NFI).](ao0c01028_0002){#fig2}

2.3. Dot Blot Assay to Determine the Effect on Aβ42 Fibrillation {#sec2.3}
----------------------------------------------------------------

Preliminary studies with ThT showed Glupep to be an effective dose-dependent inhibitor of Aβ42 fibril aggregation. The dot blot assay was performed to confirm this result.^[@ref46]^ Aβ42 (10 μM) along with different amounts of Glupep (2.5--20 μM) were co-incubated separately to form fibrillar aggregates. These samples were then spotted on a nitrocellulose membrane and then subjected to treatment with the OC antibody (detects fibrillar aggregates only). The control samples were treated with the 6E10 antibody (detects all forms of Aβ42). After measuring the intensities of the spots, Glupep showed a concentration-dependent inhibition toward Aβ42 fibril formation. Concentrations of 5, 10, and 20 μM showed inhibition of 10, 73, and 91%, respectively ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). This data supports the result of the ThT assay and confirms that Glupep effectively inhibits Aβ42 aggregation to form fibrils and hence aggregation ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)).

2.4. ThT Assay to Investigate the Inhibitory Effect on Aβ42 Oligomer Formation {#sec2.4}
------------------------------------------------------------------------------

Oligomers are believed to be the most toxic form among all the polymorphic forms of the Aβ42 peptide, which precipitate at synaptic junctions and cause neurotoxicity by disrupting synaptic plasticity.^[@ref47],[@ref48]^ Many of the aggregation inhibitors reported in the literature are known to arrest the aggregation process at an oligomeric state only; hence, they do not properly inhibit the toxicity.^[@ref49]^ In this experiment, Glupep was studied for its oligomerization inhibitory effect using the ThT assay. The Aβ42 peptide (10 μM) was incubated alone and with DAHK (10 μM), LPFFD (10 μM), and glucose (10 μM), individually at 37 °C for 1 h and then for 24 h at 4 °C. The fluorescent dye thioflavin-T (ThT) was used to detect the remaining Aβ42 oligomers (λ~ex~ = 445 nm, λ~em~ = 485 nm). The result ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}F) showed that glucose is the least effective against oligomerization. DAHK was shown to decrease the intensity by 45%. A solution co-incubated with LPFFD (positive control) prohibited oligomer formation by 57% compared to the control (Aβ42 only). Surprisingly, Glupep showed the largest effectivity and, as a result, showed that 91% of the oligomers disaggregated after incubation. Next, the same experiment was repeated using increasing concentrations of Glupep (2.5--20 μM). Solutions incubated with a higher concentration of Glupep exhibited higher efficacy than those with lower concentrations ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D), ensuring the concentration-dependent inhibitory effect of Glupep on Aβ42 oligomerization.

2.5. Detecting Inhibition of Aβ42 Oligomerization by the Dot Blot Assay^[@ref50]^ {#sec2.5}
---------------------------------------------------------------------------------

Following the ThT assay, the dot blot assay was performed to confirm Glupep's ability to inhibit oligomer formation. For this, Aβ42 (10 μM) was incubated alone and also with varying concentrations of Glupep (5, 10, and 20 μM) in PBS (10 mM, pH = 7.4) to generate the oligomers. Each sample (2 μL) was then spotted on a nitrocellulose membrane in two sets. One set was incubated with A11 antibodies, which can detect oligomers only, and the other set (control) was incubated with 6E10, which detects any form of the Aβ42 peptide. Comparing the intensities between the two sets showed a concentration-dependent inhibitory effect of Glupep against Aβ42 oligomerization ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}E). Plotting the intensity against concentration ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)) showed that unlike most of the reported aggregation inhibitors, Glupep not only inhibits the generation of more Aβ42 aggregates but also disrupts the formation of Aβ42 oligomers.

2.6. Effect of Glupep on Cu^2+^-Mediated Aβ42 Aggregation {#sec2.6}
---------------------------------------------------------

Previously, several studies have suggested that even a minimal amount of Cu^2+^ (Aβ42: Cu^2+^ = 1:0.4) can chelate and accelerate Aβ42 aggregation.^[@ref51]^ Therefore, to function as an Aβ42 aggregation inhibitor, Glupep should also have an inhibitory effect on Cu^2+^-mediated Aβ42 aggregation. To assess the inhibitory effect of Glupep, Aβ42 (10 μM) was co-incubated with Cu^2+^ (4 μM) as a control solution, and then the control solution was separately co-incubated with DAHK (10 μM), LPFFD (10 μM), glucose (10 μM), and Glupep (10 μM). Lastly, ThT (10 μM) was used to detect and quantify aggregation inhibition. The result showed that glucose has the least effect on aggregation. DAHK (copper chelator) was shown to reduce the aggregation by 32%. Positive control LPFFD was shown to inhibit the fluorescence intensity by 42%. Meanwhile, designed inhibitor Glupep showed 69% reduction in the intensity ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)). The result has confirmed the exceptional inhibitory effect of Glupep on copper (Cu^2+^)-mediated Aβ42 aggregation.

2.7. Understanding the Molecular Interactions of Glupep with Aβ42 Aggregates {#sec2.7}
----------------------------------------------------------------------------

Previous experiments have demonstrated the inhibitory activity of Glupep against Aβ42 oligomerization and fibril aggregation. Molecular docking studies were carried out with the corresponding Aβ42 monomer (PDB ID: 1IYT)^[@ref52]^ and Aβ42 fibril (PDB ID: 5KK3)^[@ref53]^ for a detailed understanding of the mechanism of inhibition. Docking studies revealed that Glupep binds to the ^6^HDSGYEVHHQKLVFFA^21^ region containing the hydrophobic core ^16^KLVFFA^21^ of the Aβ42 peptide monomer with a binding energy of −5.2 kcal/mol through polar interactions ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--D). ASP7, SER8, GLU11, VAL12, LYS16, and ASP23 amino acids were the prominent residues interacting with Glupep. Docking studies performed for the monomer with glucose, LPFFD, and DAHK showed interaction energies of −4.4, −3.8, and −4.7 kcal/mol, respectively ([Figures S16--S18](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)). Docking studies performed with the Aβ42 fibril established the interaction of Glupep with GLU11, HIS13, HIS14, VAL40, and ILE41 residues (BE of −7.2 kcal/mol) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E,F). In contrast to Glupep, DAHK, LPFFD, and glucose were shown to interact with the fibril with binding energies of −5.7, −5.9, and −4.8 kcal/mol, respectively ([Figures S8--S10](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), which are insignificant compared to that of Glupep. Moreover, this study revealed Glupep to have an additional interaction between the hydroxyl group of the attached glucose with the aspartic acid residue of the Aβ42 monomer and the histidine residue of the fibril. Interestingly, this interaction was missing in the case of LPFFD (positive control for aggregation inhibition). Altogether, the results of the study completely support the outcomes of ThT assays and Dot blot assays.

![(A) Molecular docking experiment of Glupep with the Aβ42 peptide monomer (PDB ID: 1IYT). (B) Bonding interaction of Glupep with the Aβ42 monomer. (C) Summary of interacting amino acids and molecular interactions of Glupep with the Aβ monomer. (D) Molecular docking study of Glupep with the Aβ fibrillar aggregate (PDB ID: 5KK3). (E) Bonding interaction of Glupep with the Aβ42 fibrillar aggregate. (F) Summary of interacting amino acids and molecular interactions of Glupep with the Aβ fibrillar aggregate.](ao0c01028_0003){#fig3}

2.8. Analyzing the Copper Chelation Ability of Glupep {#sec2.8}
-----------------------------------------------------

DAHK, the N-terminal ATCUN motif of HSA, was thoughtfully used in Glupep as a copper chelator, but the amide linkage between the two aspartic acid moieties concealed the N-terminal nitrogen of DAHK. Hence, assessment of Cu^2+^ chelation by Glupep was performed to check whether it has retained a similar ability with DAHK or not. For this experiment, absorption of Glupep (100uM) alone in PBS buffer (pH = 7.4, 10 mM) was measured by UV--vis spectroscopy, which exhibited an absorption maxima at 210 nm. Upon addition of Cu^2+^ (100 μM), a shoulder peak at 268 nm was formed ([Figure S11A](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), indicating successful chelation of Cu^2+^. Further, to understand the binding ratio between Glupep and Cu^2+^, a constant amount of Glupep (100 μM) was subjected to titration with different concentrations of Cu^2+^ (40--200 μM). The shoulder peak at 268 nm showed a hyperchromic shift with an increment in concentration. Saturation in this shift appeared after the concentration of Cu^2+^ crossed 100 μM, demonstrating that Glupep forms a complex with Cu^2+^ in a 1:1 stoichiometric ratio ([Figure S11B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)). This experiment additionally confirmed that Glupep retains a similar Cu^2+^ chelating ability to DAHK.

2.9. Sequestration of Copper from the Aβ42--Cu^2+^ Complex {#sec2.9}
----------------------------------------------------------

In the presence of bioreductants (ascorbate), Aβ42-bound Cu^2+^ gets reduced to Cu^+^ and initiates a reduction cycle, ultimately generating ROS.^[@ref54]^ Hence, we were interested in checking whether Glupep can sequester out Aβ-bound copper or not. For this, the inherent fluorescence of TYR10 present in Aβ was used. Due to its position and close vicinity to three histidine residues (His6, His13, His14), the fluorescence emission intensity of TYR10 can be altered by metal coordination.^[@ref55]^ It was reported that the fluorescence emission gets quenched by Cu^2+^, indicating the conformational change of the Aβ42 peptide.^[@ref56]^ Upon sequestration of this Cu^2+^, TYR10 is expected to get back its characteristic emission peak at 308 nm. The magnitude of regaining the fluorescence intensity indicates the extent of the sequestering ability.

Aβ (10 μM) was incubated in PBS (10 mM, pH = 7.4), and fluorescence emission was recorded to understand the aptitude of copper chelation by Glupep ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Emission spectra showed the characteristic peak of TYR10 at 308 nm. Following this, Cu^2+^ (10 μM) was added into the Aβ solution and co-incubated, keeping the ratio at 1:1. The emission spectra this time showed a rigorous decrement of intensity owing to the quenching of TYR10. Remarkably, the addition of Glupep (10 μM) was shown to restore the emission fluorescence to 82% ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). This signifies the ability of Glupep to chelate copper out of the Aβ--Cu^2+^ complex, in turn preventing its redox cycle.

![(A) Tyr10 fluorescence of only Aβ42 (10 μM) and Aβ42--Cu^2+^(1:1) (10 μM) in the presence and in the absence of Glupep (10 μM) in PBS buffer (10 mM, pH 7.4). (B) Bar diagram of Tyr10 normalized fluorescence intensity (NFI) measured for the Aβ42--Cu^2+^ complex in the presence and absence of 10 μM peptide Glupep. (C) Suppression of Cu^2+^-catalyzed ROS production through copper chelation via measuring the fluorescence intensity of 7-OH-CCA. (D) Bar diagram of corresponding fluorescence intensity of 7-OH-CCA at the end of 1 h. Error bar corresponds to the standard deviation of the value (\**p* ≤ 0.05).](ao0c01028_0004){#fig4}

2.10. Suppression of Metal-Mediated ROS Generation by Glupep {#sec2.10}
------------------------------------------------------------

In the AD brain, Cu^2+^ forms a complex with Aβ42 and participates in the production of reactive oxygen species (ROS) through a Fenton-type reaction. Therefore, designing a proper antioxidant that can terminate the redox cycle of Aβ--Cu^2+^ and sequentially prevent the ROS generation can be considered to be an appropriate approach to block the multifaceted toxicity in the AD. It has already been seen that Glupep can chelate and even sequester out Aβ-bound Cu^2+^. Thus, it is expected that Glupep is able to reduce Aβ--Cu^2+^-mediated ROS generation in the AD brain. Hence, to analyze whether Glupep is able to suppress redox formation or not, the ascorbate assay was performed. In this assay, Cu^2+^ was co-incubated with a natural reductant (ascorbate) to instigate the generation of hydroxy radicals, which is the most toxic form of ROS.^[@ref57]^ These hydroxy radicals convert nonfluorescent 3-coumarin carboxylic acid (3-CCA) to a fluorescence-active compound 7-hydroxy-coumarin-3-carboxylic acid (7-OH-3-CCA), which has a detectable fluorescence emission at 452 nm.

For this experiment, a solution having Cu^2+^ (5 μM), 3-CCA (50 μM), and deferoxamine (1 μM) was prepared in PBS (10 mM, pH = 7.4). Then, Glupep (10 μM), DAHK (10 μM), LPFFD (10 μM), and glucose (10 μM) were separately added to this solution. After the addition of ascorbate in a high amount (150 μM), these solutions were kept for incubation at 37 °C for the next 70 min. Throughout this incubation period, fluorescence emission of formed 7-OH-3-CCA was recorded as a function of time at 452 nm (λ~ex~ = 395 nm), keeping an interval of 5 min ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). Glupep showed 63% reduction in generation of hydroxyl radicals at 70 min with respect to the control (Aβ--Cu^2+^), indicating that Glupep prevents the reduction process and forms a dormant redox complex with Cu^2+^. On the other hand, comparing the result with that of positive control DAHK (61% reduction compared to control), Glupep showed a very similar outcome, indicating that the incorporation of DAHK into Glupep has no significant effects on its Cu^2+^-chelating and ROS-inhibiting ability. Solutions containing LPFFD and glucose showed relatively higher fluorescence intensity, indicating their inability to reduce ROS generation. These outcomes ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}D) suggested that even in a natural reducing environment, Glupep put a halt in the reduction process and in Aβ--Cu^2+^-mediated ROS generation.

2.11. Cell Viability Studies {#sec2.11}
----------------------------

Previous experiments performed in this study have suggested Glupep to be a multifunctional inhibitor of Aβ42 aggregation and ROS generation. The next step is to perform in vitro studies to confirm its efficiency within cells. For this, the viable cellular concentration of Glupep must be determined by performing the MTT assay in rat pheochromocytoma (PC12) cells. Generally, the MTT assay determines the reduction potential of a live cell through colorimetric assessment. NADPH-dependent cellular enzyme oxidoreductase present in live cells reduces tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to form purple formazan.^[@ref58]^ Dead cells are incapable of carrying out this reduction process. Formazan produced in this reaction can be quantified by absorbance spectrometry (within 500--800 nm wavelength), indicating the percentage of viable cells present.

Herein, the PC12 cells were incubated in the presence of different increasing amounts (1.525 to 50 μM) of Glupep at 37 °C for 24 h, and then the MTT assay was performed. No cytotoxic effects were observed for Glupep at high concentrations of 50 and 100 μM ([Figure S12](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), confirming Glupep to be safe for performing cell-based assays.

2.12. Restoring Cell Viability in the Presence of Aβ--Cu^2+^-Mediated Toxicity {#sec2.12}
------------------------------------------------------------------------------

In the AD brain, by forming a complex with Aβ42, copper not only increases the extent of Aβ42 aggregation but also induces ROS generation. In this context, to develop a multidirectional inhibitor, it must not only inhibit the aggregation and ROS generation but also should protect cells from toxicity. Hence, to determine the potential of Glupep, PC12 cells were treated with the Aβ--Cu^2+^ complex (10 μM) and a high amount of natural reductant, ascorbate (200 μM), to induce toxicity. The cells were then incubated with different amounts of Glupep (1--20 μM). The MTT assay was then performed to determine the percentage of rescued cells by Glupep ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). Aβ42--Cu^2+^-treated cells showed the highest toxicity with a cell viability of ∼25% compared to untreated cells showing 100% viability. Meanwhile, the cell viability showed to increase 21% upon treating with Glupep at a concentration of 10 μM. Doubling the concentration of Glupep to 20 μM showed enhancement in the cell viability to 70% ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A), thus suggesting the ability of Glupep to rescue the cells from Aβ42--Cu^2+^-mediated toxicity in a dose-dependent manner. For a comparative assessment, a similar procedure was then repeated with LPFFD (10 μM), DAHK (10 μM), and glucose(10 μM). Comparing the cell viability with that of Aβ42--Cu^2+^-treated cells ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B) demonstrated LPFFD, DAHK, and glucose to either have no effect or a very negligible effect in restoring the cell viability.

![(A) Restoration of cell viability by Glupep in Aβ42--Cu^2+^ (1:1)-mediated toxicity (Cu^2+^:10 μM), showing increased cell viability upon treatment with increasing concentrations of Glupep. (B) Comparing the ability to restore cell viability with glucose, LPFFD, DAHK, and Glupep in Aβ42--Cu^2+^ (1:1)-mediated toxicity showing increased cell viability upon treatment with increasing concentrations of Glupep. (C) Bar diagram for the DCFDA assay with increasing concentrations of Glupep. (D) Bar diagram for the DCFDA assay 10 μM glucose, LPFFD DAHK, and Glupep. Experiments were repeated in triplicate (*n* = 3), and the standard deviation (SD) was calculated, which is represented by the error bars. Error bar corresponds to the standard deviation of the value (\**p* ≤ 0.05, \*\**p* ≤ 0.03).](ao0c01028_0005){#fig5}

2.13. In Vitro Assessment of ROS Suppression {#sec2.13}
--------------------------------------------

As the primary in vitro analysis showed that Glupep could protect cells from Aβ42--Cu^2+^-induced toxicity, we were curious to know what kind of in vitro effect Glupep will show on Aβ--Cu^2+^-mediated ROS generation. The effect of Glupep on Aβ42--Cu^2+^-induced ROS generation was studied using the DCFDA assay in PC12 cells.^[@ref59]^ DCFDA (2,7-dichlorofluorescein diacetate) is a nonfluorescent compound utilized to quantify ROS strains such as hydroxyl, peroxyl, and other ROS species. DCFDA reacts with the ROS molecules formed from the Aβ42--Cu^2+^-mediated redox cycle and gets oxidized to fluorescent 2,7-dichlorofluorescein (DCF, λ~ex~ = 495 nm and λ~em~ = 529 nm). The PC12 cells were treated with DCFDA before incubating with Aβ42--Cu^2+^(10 μM), a high amount of natural reductant ascorbate (200 μM), and amounts of Glupep. Cells treated with increasing concentrations of Glupep, that is, 5, 10, and 20 μM, showed 25, 36.43, and 64.18% reduction in fluorescence intensity, respectively, compared to cells treated without Glupep ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C), indicating the weaker presence of intracellular ROS with Glupep treatment. This in vitro ROS suppression demonstrated by Glupep can be correlated to its ability to sequester out copper from the Aβ42--Cu^2+^ complex. To compare this result with those of the component molecules, the assay was repeated with DAHK (10 μM), LPFFD (10 μM), and glucose (10 μM). Data ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D) revealed that LPFFD and glucose have no such antioxidant activity, and DAHK being the copper chelator reduced the fluorescence intensity by ∼25% compared to control. Compared to the positive control (DAHK), Glupep this time showed reduction in the intensity by almost ∼32%. To further confirm this in vitro antioxidant activity of Glupep, we have performed imaging studies with DCFDA with differentiated PC12 cells treated with the Aβ42--Cu^2+^ complex. As expected, 20 μM Glupep showed reduction in the fluorescence intensity of DCFDA, as observed in Aβ42--Cu^2+^ complex-treated cells ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}), and its DCFDA fluorescence intensity was more comparable to that of the untreated control PC12 cells ([Figure S13](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), which is in agreement with the previous studies performed to elucidate the antioxidant potential of Glupep. Hence, this result shows that the Glupep molecule designed to terminate the Aβ42--Cu^2+^-mediated redox cycle is confirmed to possess the desired characteristics, and also, the result is in good support of the outcome obtained from the ascorbate assay.

![Live-cell microscopy images of PC12-derived neurons stained with DCFDA. DIC images of (A) untreated control PC12 cells, (B) Aβ + Cu^2+^-treated cells (10 μM) and (C) Aβ + Cu^2+^-treated cells (10 μM) in the presence of 20 μM Glupep (GP). DCFDA images of (D) untreated control cells, (E) cells treated with Aβ + Cu^2+^ (10 μM), and (F) cells treated with Aβ + Cu^2+^ (1:2) in the presence of 20 μM Glupep (GP). Scale bars corresponding to 20 μm.](ao0c01028_0006){#fig6}

2.14. In Vitro Assessment of Mitochondrial Membrane Potential (MMP) {#sec2.14}
-------------------------------------------------------------------

Aβ42--Cu^2+^ leads to the induction of oxidative stress in neurons by the generation of ROS, which ultimately leads to mitochondrial dysfunction and depolarization of the mitochondrial membrane potential (MMP). Mitochondrial dysfunction is associated with the induction of cell death through activation of the apoptotic pathway. For assessing the mitochondrial membrane potential, the JC-1 assay has been performed through the quantitative analysis of the green/red intensity ratio. It was observed that Aβ42--Cu^2+^ at a 10 μM concentration leads to an abnormal increase in the green/red ratio in the PC12-derived neurons ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A,B), indicating that it induces MMP depolarization, which would ultimately result in mitochondrial dysfunction and cell death. However, in the presence of Glupep at 20 and 10 μM concentrations, the green/red ratio of Aβ42--Cu^2+^ is severely reduced ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}C,D) to the extent that it is comparable to the untreated control ([Figure S14](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)). Hence, we can conclude that Glupep is a potent antioxidant molecule with the capability of reversing the various characteristics associated with the Aβ42--Cu^2+^-mediated redox cycle.

![MMP assay with the JC1 dye of PC12-derived neurons (A) for untreated control PC12 cells, (B) after treatment with 10 μM Aβ + Cu^2+^, (C) when cells are co-incubated with Aβ + Cu^2+^ and 20 μM Glupep, and (D) when cells are co-incubated with Aβ + Cu^2+^ and 10 μM Glupep.](ao0c01028_0007){#fig7}

2.15. Evaluation of Serum Stability {#sec2.15}
-----------------------------------

The above results suggest that Glupep not only inhibits Aβ42 aggregation but also has a similar ability to terminate ROS generation. However, a critical challenge for a peptide molecule to be considered as a drug candidate is its susceptibility toward serum peptidases and lower bioavailability.^[@ref60]^ It has been described before that glycosylation of a peptide molecule has resulted in increased serum stability and enhanced bioavailability.^[@ref61]^ Further, it also increases the peptide's side-chain protection from oxidation.^[@ref62]^ Thus, we have attached the glucose moiety of our peptide at its N-terminal through thioconjugation to develop Glupep.

To evaluate this strategy by determining the serum stability of the peptides (DAHK, LPFFD, LPFFDDAHK) and glycopeptide (Glupep), molecules were incubated with 50% human blood serum for 24 h at 37 °C and every 0, 4, 6, 12, and 24 h, the quantity of undamaged peptide was estimated using RP-HPLC ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}A). Among all the molecules, DAHK was shown to have the least stability against serum proteases, with only 13% remaining intact after 24 h. LPFFD proved to be the second most susceptible peptide as only 32% of it remained undamaged after 24 h. LPFFDDAHK also showed to be unstable in serum as only 40% of it was intact after 24 h. Interestingly, attaching the glucose molecule with LPFFDDAHKK and forming Glupep has shown a positive impact on the stability as 84% of the Glupep was still detected intact even after 24 h, that is, 44% more than the corresponding non-glycosylated analog LPFFDDAHK. This result suggested that the glycopeptide Glupep has potential as a drug candidate for AD.

![(A) Serum stability of Glupep. Peptides (DAHK, LPFFD, LPFFDDAHK, and Glupep) were incubated in human blood serum (HBS) and analyzed over a duration of 24 h. Each experiment was repeated three times (*n* = 3), and the standard deviation (SD) was calculated, which is represented by the error bars. Error bar represents the value of the SD (\**p* ≤ 0.03). (B) ESI-MS mass spectra of mice brain homogenate treated with Glupep. Expected mass (*m*): 1338 Da, observed mass: 669 Da \[*m*/2\], 1338 Da \[*m*\].](ao0c01028_0008){#fig8}

2.16. Inspecting Blood--Brain Barrier Permeability^[@ref58],[@ref59]^ {#sec2.16}
---------------------------------------------------------------------

Any molecule that is expected to have therapeutic relevance to Alzheimer's disease must possess the ability to cross the blood--brain barrier (BBB). For this reason, Glupep was also inspected whether it has a BBB permeation ability or not. For this experiment, a 2.5 mM solution of Glupep in saline was prepared, and a volume of 100 μL was injected intraperitoneally 6 h before the mice were sacrificed. After 6 h, the brain was isolated to prepare a homogenate in acetonitrile. Then, ESI-MS spectra revealed the presence of Glupep molecular peaks, confirming Glupep's ability to cross the BBB ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B). This experiment was repeated with the non-glycosylated counterpart of Glupep, i.e., LPFFDDAHK. The ESI-MS spectra showed no molecular mass peak of LPFFDDAHK ([Figure S15](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), thus confirming that glycosylation has increased the BBB permeability of Glupep.

![Mechanism for inhibition of metal-mediated and metal-independent amyloid toxicity.](ao0c01028_0009){#fig9}

3. Conclusions {#sec3}
==============

In this paper, we showcased the design of a new glycopeptide-based inhibitor, which has the ability to target multiple vital issues of AD by targeting Aβ42 aggregation and metal-induced ROS generation. The glycopeptide-based inhibitor was developed (Glupep) by coupling a naturally occurring copper-chelating motif (DAHK) present in human serum albumin (HSA) with Aβ42 aggregation inhibitory peptide LPFFD. We found that Glupep inhibits both Cu^2+^-dependent and Cu^2+^-independent formation of Aβ42 aggregates (oligomers and fibrils), and like native DAHK, Glupep can also hamper the Aβ42--Cu^2+^ redox cycle by extracting out the Cu^2+^, thus helping in maintaining a dormant redox state. We have also shown that Glupep impedes ROS generation both in vitro and in vivo*.* It can also hold back depolarization of MMP in PC12-derived neurons induced by the Aβ42--Cu^2+^ redox cycle. Cell viability assay reveals that Glupep not only protects the cells from Aβ42--Cu^2+^-induced toxicity but also offers significantly better protection compared to its building components LPFFD and DAHK peptides. This study enabled us to overcome one of the significant concerns, serum susceptibility of therapeutic peptides, by attaching a glucose moiety to the N-terminal of Glupep, which helps it cross the blood--brain barrier effectively. Considering all these aspects, we envision that this glycopeptide-based inhibitor Glupep with its multifunctional inhibitory effects will contribute to designing efficient therapeutic leads against AD.

4. Methods {#sec4}
==========

4.1. Chemicals {#sec4.1}
--------------

All Fmoc protected amino acids and Rink amide resin was bought from Novabiochem (Germany). All the piperidines and 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) were purchased from Spectrochem. Dichloromethane (DCM), *N*,*N*′-dimethylformamide (DMF), 4-dimethylaminopyridine (DMAP), hydrazine hydrate, methanol, ethyl acetate, 3-coumarin carboxylic acid (3-CCA), thioflavin-T, trifluoroacetic acid, hydrogen peroxide (30% solution), diethyl ether, acetic anhydride, deferoxamine, and 2,7-dichlorofluorescein diacetate (DCFDA) were purchased from Merck (Germany). 3-Mercaptopropionic acid and boron trifluoride etherate were purchased from TCI Pvt. Ltd. β-[d]{.smallcaps}-Glucose was obtained from Qualligens. Copper chloride was bought from SRL Pvt., Ltd. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethylsulfoxide (DMSO) for cell culture were purchased from Sigma-Aldrich. All the different sera and culture media were bought from Invitrogen. HPLC-grade water and acetonitrile were procured from J. T. Baker. β-Amyloid (1--42) was acquired from Alexotec (Sweden). Nitrocellulose membranes were obtained from Merck Millipore. Primary antibodies 6E10, A11, and OC were obtained from Bio Legend, Thermo Scientific, and Millipore, respectively. The BD Mitoscreen (mitochondrial membrane potential detection) JC-1 kit was bought from BD Biosciences. RP-HPLC (Shimadzu) with Symmetry C-18 (Waters) was used for purification of the glycopeptide and peptides. All compounds were used without further purification.

4.2. Synthesis and Purification of Peptides and Glycopeptides {#sec4.2}
-------------------------------------------------------------

The solid-phase peptide synthesis (SPPS) procedure was followed for synthesizing the peptides (DAHK, LPFFD, and LPFFDDAHK) using Rink amide AM resin. Fmoc-protected forms of the resin and amino acids were utilized to synthesize the peptides. Fmoc groups were deprotected using a solution of 20% piperidine in DMF. Resin-bound peptides were cleaved using a cleaving cocktail solution of TFA (91%), EDT (3%), MilliQ water (3%), and phenol (3%). The peptides were then precipitated dropwise in the precooled diethyl ether and stored at −20 °C. Diethyl ether containing the crude peptide was centrifuged and purified by RP-HPLC ([Figures S2A, S3A, and S4A](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), and the purified samples were characterized by ESI or MALDI mass spectroscopy ([Figures S2B, S3B, and S4B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)).

To synthesize the glycopeptide (Glupep), a convergent approach was followed (Scheme S1), where the peptide component (LPFFDDAHK) and glycocomponent (3-(2,3,4,6-tetraacetyl-α-[d]{.smallcaps}-glucopyranosyl)thiopropionic acid) were presynthesized. After the last deprotection step, the glycocomponent was coupled to the N-terminal of the resin-bound peptide. Acetylated glucose was deprotected using a solution of hydrazine hydrate in water (1:9). The glyco-coupled peptide was cleaved using a similar procedure as described earlier. Further purification was done by RP-HPLC ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)), and the purified samples were characterized by ESI mass spectrometry ([Figure S1B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf)).

4.3. Preparation of the Aβ42 Fibril and Oligomer Sample {#sec4.3}
-------------------------------------------------------

The Aβ42 peptide was dissolved in hexafluoroisopropanol (HFIP) and kept for 1 h to dissociate the preformed aggregates.^[@ref65]^ HFIP was evaporated under a gentle nitrogen flow to get a white precipitate, which was then dried under vacuum and stored at −20 °C for further use. To prepare stock solution, Aβ42 was dissolved first in the least possible amount of DMSO, and then the required concentration was achieved by making up the volume with PBS buffer (pH = 7.4, 10 mM).

To obtain the fibril aggregates, a desired amount of Aβ42 in PBS (pH = 7.4, 10 mM) was kept in constant agitation at 37 °C for 24 h.^[@ref66]^ To validate the formation of fibrils, ThT and dot blot assays were performed. Then, to prepare the oligomeric samples, Aβ42 peptide solution in PBS was incubated at 37 °C for 1 h and then was transferred to be incubated at 4 °C for the next 24 h. Then, the solution was centrifuged at 15,000*g*, and the supernatant of the solution was used in the experiments.^[@ref46]^ The formation of Aβ42 oligomers was confirmed using similar dot blot and ThT assays.

4.4. Preparation of the Cu^2+^-Mediated Aβ42 Aggregate Sample {#sec4.4}
-------------------------------------------------------------

Cu^2+^-mediated Aβ42 aggregate samples were prepared using a substoichiometric amount of Cu^2+^. Aβ42 and Cu^2+^ were mixed in a 1:0.4 ratio in PBS (10 mM, pH = 7.4) to prepare a final solution with a volume of 50 μL. The solution was kept for incubation at 37 °C at 150 rpm of constant shaking for 72 h. The formation of aggregates was confirmed by the ThT assay.

4.5. Determining the Inhibition of Aβ42 Aggregates Using the ThT Fluorescence Assay {#sec4.5}
-----------------------------------------------------------------------------------

Aβ42 (10 mM) was co-incubated with 10 μM of all the compounds (i.e., glucose, DAHK, LPFFD, and Glupep) to form fibrils and oligomers according to the mentioned procedure. For the control experiment, only PBS was used. A 100 μM stock solution of ThT in PBS was prepared from which a final concentration of 10 μM was used to quantify the Aβ42 fibrillar and oligomeric aggregates remaining intact. The fluorescence intensity was determined using a Quanta Master spectrofluorometer (QM-40) at an excitation wavelength of 435 nm and an emission wavelength of 485 nm (slit width = 1.25 nm).^[@ref63],[@ref64]^ The fluorescence intensity of the blank solution was subtracted from each fluorescence measurement. The fluorescence intensity of only the Aβ42 solution was fixed as 100%, and all the data were measured accordingly. The whole procedure was repeated again with different concentrations of Glupep (2.5--20 μM) and also repeated to detect the inhibition of Cu^2+^-mediated aggregation. All the experiments were repeated three times, and a *t* test was performed to analyze the data.

4.6. Dot Blot Analysis {#sec4.6}
----------------------

Different amounts of Glupep (5, 10, and 20 μM) were mixed individually with Aβ42 (10 μM) in two separate sets of solutions. One set was subjected to incubation with constant shaking at 37 °C for 48 h to form fibrils. The other one was incubated at 37 °C for 1 h and then kept at 4 °C for 24 h to form oligomers. Then, the incubated solutions were centrifuged at 15,000*g* for 15 min and the supernatant was spotted on a nitrocellulose membrane. To block the nonspecific sites, the paper was soaked in 5% bovine serum albumin (BSA) in TBST buffer for 1 h at 37 °C. The nitrocellulose papers were reacted individually with the primary antibodies 6E10 (detects all forms of Aβ42, 1:3000), A11(detects specifically oligomers, 1:3000), and OC (detects fibrils only, 1:3000) overnight at 4 °C. The membranes were then washed three times, each with TBST buffer for 5 min. They were then kept for incubation along with horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit secondary antibodies (1:10000) for a minimum of 1 h at 37 °C. All the membranes were again washed with TBST buffer three times for 5 min. Lastly, the membranes were reacted with an enhanced chemiluminescence agent for 2 min. Biorad ChemiDoc Touch was used to record the chemiluminescence intensity. The relative decrement in aggregation was determined by comparing the chemiluminescence intensity to that of the control (only Aβ).^[@ref67]^

4.7. Molecular Docking Study {#sec4.7}
----------------------------

AutoDock Vina version 1.1.2^[@ref68]^ was used to carry out docking studies. All the ligand structures (i.e., Glupep, LPFFD, DAHK, glucose) were energy-minimized in Avogadro software using the MMFF94 force field. The protein structures of the Aβ42 monomer (PDB ID: 1IYT) and fibril (PDB ID: 5KK3) were redeemed from the RCSB Protein Data Bank.^[@ref53]^ Blind docking studies were performed to recognize the binding sites of the highest probability. PyMOL (The PyMOL Molecular Graphics System, version 1.7.4 Schrödinger, LLC) was used to analyze results and record poses.

4.8. ·OH Radical Generation Measurement by the Ascorbate Assay {#sec4.8}
--------------------------------------------------------------

Solutions of 3-CCA (50 μM) and Cu^2+^ (5 μM) were prepared in PBS (10 mM, pH = 7.4), and each peptide (DAHK, LPFFD), glucose, and the glycopeptide Glupep were added independently to this solution to have a final concentration of 10 μM. Next, deferoxamine with a final concentration of 1 μM was added to this solution. Deferoxamine was added to inhibit the iron (Fe^2+^ and Fe^3+^ that are present in PBS) from taking part in the redox cycle. Lastly, an excess amount of reductant sodium ascorbate (150 μM) was added, and the solution was incubated for the next 70 min. Generated hydroxyl radicals converted nonfluorescent 3-CCA to fluorescent 7-OH-CCA (λ~ex~ = 395 nm and λ~em~ = 452 nm).^[@ref34]^ A Quanta Master spectrofluorometer (QM-40) was used to detect the fluorescence intensity at 452 nm as a function of ROS generation.

4.9. Tyrosine Fluorescence Spectroscopy {#sec4.9}
---------------------------------------

The intrinsic fluorescence of TYR10 (excitation: 285 nm and emission: 308 nm) of the Aβ42 peptide gets diminished upon binding with Cu^2+^.^[@ref55]^ Treating the Aβ42--Cu^2+^ complex with the chelating agent Glupep is expected to extract Cu^2+^ out and restore the fluorescence intensity. Therefore, the fluorescence intensity at 308 nm was measured to understand the extent of Cu^2+^ removal from the Aβ42--Cu^2+^ complex by Glupep. For this, a solution of Aβ42 (10 μM) was prepared in PBS buffer (10 mM, pH = 7.4), and fluorescence was measured at 308 nm (positive control). Next, Cu^2+^ was added to the same solution to make a concentration of 10 μM. After incubating for the next 30 min at 37 °C, fluorescence was again recorded to have a large decrement in fluorescence (negative control). Finally, Glupep (10 μM) was added to the solution, and once again, fluorescence was measured.

4.10. Serum Stability Assay {#sec4.10}
---------------------------

Lipid components of the serum were precipitated by centrifuging it at 15,000*g* for 20 min. Solutions (100 μM) of the peptides (DAHK, LPFFD, LPFFDDAHK) and Glupep were incubated with the supernatant for the next 24 h At every 0, 4, 6, 12, and 24 h, triplicate solutions of 100 μL were taken, and 100 μL of acetonitrile was added to precipitate out serum proteins. To inhibit the serum protease activity, these solutions were kept at 4 °C for 30 min. Then, the solutions were centrifuged again, and the supernatant was analyzed using RP-HPLC (flow rate:0.7 mL/min) to detect the remaining peptides and glycopeptides.^[@ref69]^ Lastly, the change in the intensity profile of the compounds with time was plotted.

4.11. In Vitro Evaluation of Aβ42--Cu^2+^-Mediated Toxicity {#sec4.11}
-----------------------------------------------------------

This experiment was performed by seeding PC12 cells in a 96-well plate at 37 °C in a 5% CO~2~ environment for 24 h. After 24 h, the media were replaced with media having a low serum concentration (2% serum concentration). Then, the cells were incubated with Aβ42--Cu^2+^ (10 μM) in the individual presence of peptides (10 μM of DAHK and LPFFD), glucose (10 μM), and Glupep (10 and 20 μM) with a large amount of ascorbate (100 μM). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (10 mg/mL) was added to each well and incubated at 37 °C for 4 h. Cellular reductase enzymes of viable cells reduce MTT into purple-colored formazan. After 4 h, the media were discarded, and the formazan was dissolved with DMSO/MeOH (1:1 v/v). The absorption intensity of formazan was determined as a function of viable cells at 570 nm using a microplate ELISA reader.^[@ref70]^ The percentage of cell viability was determined by using the following equation on the absorption data.

4.12. Performing the JC-1 Assay to Assess the MMP {#sec4.12}
-------------------------------------------------

Initially, we plated PC12 cells in six-well plates and cultured them overnight. Next, the cells were treated with 100 ng/mL NGF in differentiation medium and differentiated into neurons in 5 days. After this, the PC12-derived neurons were treated with Aβ42--Cu^2+^ (10 μM) and Aβ42--Cu^2+^ (10 μM) along with Glupep (10 μM and 20 μM) for 24 h. Next, the cells were dislodged, and the intracellular mitochondrial membrane potential (Δψm) was measured with the aid of BD MitoScreen following the manufacturer's instructions. In brief, first, the dislodged cells were treated with a working concentration of JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazolcarbocyanine iodide) dye diluted in 1× assay buffer, which is prepared from a 10× assay buffer. JC-1 is a membrane-permeable dye that can penetrate into cells and induce fluorescence, reflecting the status of the membrane polarization (Δψ). The cells were incubated with the dye for 25 min at 37 °C in a CO~2~ incubator. After that, the cells were washed with the assay buffer, and the membrane potential was determined through FACS (LSRFORTESA) at 527 and 590 nm.

4.13. Measuring the Intracellular ROS Level by the DCFDA Assay {#sec4.13}
--------------------------------------------------------------

To explore the effect of Glupep on Aβ42--Cu^2+^-mediated intracellular oxidative stress, the DCFDA assay was performed. PC12 cells were seeded on a 96-well plate at 37 °C in a 5% CO~2~ environment. After incubation for 20 h, when the cells were properly grown, the media were changed and kept for another incubation period of 4 h Next, the cells were washed with PBS and incubated with 2,7-dichlorodihydrofluoresceindiacetate (DCFDA, λ~ex~ = 495 nm, λ~em~ = 529 nm) for another half an hour. Cells were washed again and incubated with Aβ42--Cu^2+^ (10 μM) and ascorbate (300 μM) as a control solution. The control solution was incubated alone and separately with peptides (10 μM LPFFD and DAHK), glucose (10 μM), and Glupep (5, 10, and 20 μM) at 37 °C for 40 min. Cells were washed, and the fluorescence intensity at 529 nm was measured using a microplate reader. The significance of the result was determined by performing two-tailed Student's *t* test.

4.14. Blood--Brain Barrier Permeability Assay {#sec4.14}
---------------------------------------------

Mice were divided into two groups, each containing three mice. A solution of Glupep (2.5 mM) was made in saline. Then, 100 μL of the saline solution was injected intraperitoneally into the first group, keeping a dosage value of 10 mL/kg body weight. The second group was treated in the same way as nonglycosylated LPFFDDAHK. After 6 h, mice were anesthetized properly before subjecting to sacrifice. Blood was drained out totally from the body through transcardial perfusion. After collecting the brain in PBS, the meninges and blood vessels were carefully removed. The cortex was dissected out from the brain to prepare a homogenate in acetonitrile--water solution (1:1). It was then centrifuged at 10,000*g* for 10 min to separate out the brain vasculature, red blood cells, and brain nuclei.^[@ref71]^ The supernatant was then detected through mass spectroscopy for the presence molecular peaks of Glupep and LPFFDDAHK.

4.15. Data Analysis {#sec4.15}
-------------------

Images of the dot blot study were analyzed using Image J software. To measure spectroscopic data and histograms, Origin 8.5 pro software was used. Statistical calculations were done by performing ANOVA and two-tailed Student's *t* test. Statistical values of \**P* ≤ 0.05 and \*\**P* ≤ 0.03 were allocated for different experiments accordingly.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c01028](https://pubs.acs.org/doi/10.1021/acsomega.0c01028?goto=supporting-info).Scheme of Glupep, synthetic procedure, HPLC chromatogram and mass spectrum, densitometric plots of dot blot assays, ThT fluorometric assay in the presence of copper, several molecular interaction studies, UV--vis spectra, MTT assay, quantitative image analysis of the DCFDA microscopic study, quantitative bar diagram representation of JC1 data, and mass spectra of mice brain extract ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01028/suppl_file/ao0c01028_si_001.pdf))
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